Comparative prognostic relevance of breast intra-tumoral microvessel density evaluated by CD105 and CD146: A pilot study of 42 cases

详细信息    查看全文

• 作者：Leandro Marcelo Martinez^a ; Vivian Labovsky^a ; Marí ; a de Lujá ; n Calcagno^b ; Kevin Mauro Davies^c ; Herná ; n Garcia Rivello^c ; Alejandra Wernicke^c ; Juan Carlos Calvo^d ; Norma Alejandra Chasseing^a ; ^{alejachase@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; ^{achasseing@ibyme.conicet.gov.ar" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Breast cancer ; Intra-tumoral microvessel density ; CD105 ; CD146 ; Prognostic significance
• 刊名：Pathology - Research and Practice
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：212
• 期：4
• 页码：350-355
• 全文大小：1131 K

文摘

Angiogenesis is a key process for metastatic progression. While it has been established that the evaluation of breast tumoral microvessel density by CD105 marker is a potential prognostic parameter, its evaluation by CD146 marker has been poorly studied.

Aim

The purpose of this study was to compare the prognostic value of intra-tumoral microvessel density assayed by CD105 and CD146 in early breast cancer patients.

Methods

42 women with breast infiltrative ductal carcinoma (I and II-stages) were retrospectively reviewed. Intra-tumoral microvessel density was immunohistochemically examined using antibodies anti-CD105 and CD146 in paraffin-embedded tissues, and their association with classical prognostic-markers, metastatic recurrence, metastasis-free survival and overall survival was analyzed.

Results

High microvessel density assessed by CD146 was significantly associated with a higher risk of developing metastasis (p = 0.0310) and a shorter metastasis-free survival (p = 0.0197). In contrast, when we used the CD105-antibody, we did not find any significant association. Finally, CD146 showed to be an independent predictive indicator for metastasis-free survival (p = 0.0055).

Conclusion

Our data suggest that the intra-tumoral microvessel density evaluated by CD146 may be a more suitable predictor of metastatic development than that evaluated by CD105 in early breast cancer.